LOOK FAMILIAR? As we age, our ability to heal decreases BONE SKIN CARTILAGE

Transcription

1 GUY COOK, CEO

2 LOOK FAMILIAR? As we age, our ability to heal decreases BONE SKIN CARTILAGE 2

3 AGE-RELATED FUNCTIONAL DECLINE 15-YEAR-OLD STEM CELLS active 65-YEAR-OLD STEM CELLS dormant 3

4 EXTRACELLULAR MATRIX (ECM) TECHNOLOGY [ source: Deans RJ and Mosely AB. (2000) Mesenchymal stem cells: Biology and potential clinical uses. Experimental Hematology 28: l ] 4

5 EXTRACELLULAR MATRIX Directed Scaffold Technology Cultured stem cells secrete extracellular matrix (ECM) which, once decellularized, can be used for tissue engineering purposes and other applications Engineered stem cell ECM-based products can optimize patients own stem cells for: Migration to the site of injury (homing) Engraftment Proliferation Differentiation Vascularization Tissue Regeneration Rejuvenation of Old MSCs Using Young ECM tissue culture plastic young ECM old ECM young MSCs old MSCs expansion and replating on various surfaces [ Sun Y, et al. (2011) Rescuing replication and osteogenesis of aged mesenchymal stem cells by exposure to a young extracellular matrix. FASEB Journal 25: ] 5

6 OUR INNOVATION: EXTRACELLULAR MATRIX (ECM) Stem cells harvested from youthful donors Amplified Growth factors film-like substrate U.S. Patent Application: MODIFIED EXTRACELLULAR MATRIX FOR ENHANCED STEM CELL HOMING AND ENGRAFTMENT 6

7 OUR VALUE PROPOSITION FOR PATIENTS Scaffold ECM Matrix Superior Scaffold + = Directed scaffold Regenerates properly Promotes natural healing 7

8 EXTRACELLULAR MATRIX (ECM) TECHNOLOGY The same ECM technology can be used to grow a cancerous tumor outside the body Question: Why would we want to grow a tumor outside of the body? Answer: Diagnostics. 8

9 IN VITRO CANCER DIAGNOSTICS TECHNOLOGY Identifying drug leads, validating targets, and moving towards personalized medicine Lattice Biologics in collaboration with Dr. David Andrews lab at Sunnybrook Research Institute 9

10 EXTRACELLULAR MATRIX [ Baker BM and Chen CS (2012) Deconstructing the third dimension How 3D culture microenvironments alter cellular cues. Jour Cell Sci 125: ] Recapitulating the tumor microenvironment using human ECM and 3D tissue culture The use of human tissuederived ECM in a gel-like application provides a matrix that allows cancer cells to replicate in vivo behavior. Exposure to cell viability factors prevents tumor cells from reverting to a quiescent state, a confounding issue present in traditional 2D monolayer culture. [ Gilkes DM, et al (2014) Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nature Reviews Cancer 14, ] 10

11 HYPERSPECTRAL SPECTROSCOPY Use of proprietary multichromatic dyes, high content imaging and analysis can decipher pathways altered in cancerous tissue Improving upon traditional approaches to cancer treatment: 1. Use of patient-derived cells 2. More accurately mimic the tumor microenvironment in vitro 3. Decipher affected cell pathways 4. Predict appropriate drug treatments [ Andrews D, et al. Unpublished results ] 11

12 PERSONALIZED MEDICINE APPROACH Treatments for resistant cancers can be customized based on in vitro results [ Niederst MJ and Engelman JA (2013) Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 6: re6 ] The challenge is to develop accurate drug screens using the patient s own cells which have been grown in a dish. This requires the effective reproduction of the 3D tumor microenvironment, which we are accomplishing through humanderived ECM and optimal growth conditions. [ Crystal AS, et al. (2014) Patient derived models of acquired resistance can identify effective drug combinations for cancer. Science 346: ] This approach can be exploited to predict the best drug treatment regimen for patients who may have already endured previous treatments and have developed a resistant cancer. 12

13 THANK YOU! CONTACT: Lattice Biologics Ltd N 90th Street Ste#101 Scottsdale, AZ Guy Cook - CEO GCook@latticebiologics.com Cheryl Farmer - CFO CFarmer@latticebiologics.com NOW TRADING! Lattice Biologics Ltd. is traded as TSX-V: LBL OTCBB: BLVKF 13